Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Phase I Trial
100%
Malignant Peripheral Nerve Sheath Tumor (MPNST)
100%
Measles Virus
100%
Intratumoral Administration
100%
Neurofibromatosis Type 1 (NF-1)
76%
Neurofibromatosis Type I
76%
Virus
46%
Tumor
46%
Tumor Cells
23%
After Surgery
15%
Survival Rate
15%
Early Mortality
7%
Promising Therapeutics
7%
High Density
7%
Life Expectancy
7%
Tumor Killing
7%
Human Sodium Iodide Symporter (hNIS)
7%
Residual Tumor
7%
Intratumoral Injection
7%
Non-invasive Monitoring
7%
Poor Survival
7%
Human Body
7%
Antimeasles Antibody
7%
Oncolytic Virus
7%
Clinical Impact
7%
Effective Treatment
7%
Antitumor Activity
7%
Malignant Cells
7%
Therapeutic Agents
7%
In Cancer
7%
Head-and-neck
7%
Multiple Myeloma
7%
Brain Tumor
7%
Recurrent Disease
7%
Maximum Tolerated Dose
7%
Chemotherapy
7%
Breast Cancer
7%
Improved Outcomes
7%
Major Complications
7%
Oncolytic Viral Therapy
7%
Life-limiting
7%
Well Tolerated
7%
Aggressive Histology
7%
Ovarian Cancer
7%
Oncolytic Therapy
7%
New Therapies
7%
First Application
7%
Leukemia
7%
Bloodstream
7%
Treatment Options
7%
Breast Cancer Tumor
7%
Trunk
7%
Recurrent Tumor
7%
Target Receptors
7%
Cancer-associated
7%
Medicine and Dentistry
Measles Virus
100%
Phase I Trials
100%
Intratumoral Drug Administration
100%
Malignant Peripheral Nerve Sheath Tumor
100%
Neurofibromatosis Type I
76%
Virus
46%
Tumor
38%
Cancer
23%
Tumor Cell
23%
Neoplasm
23%
Survival Rate
15%
Therapeutic Agent
7%
Life Expectancy
7%
Sodium Iodide Symporter
7%
Breast Cancer
7%
Antineoplastic Activity
7%
Neck
7%
Effective Treatment
7%
Treatment Option
7%
Histology
7%
Intracranial Tumor
7%
Tumor Recurrence
7%
Recurrent Disease
7%
Receptor
7%
Oncolytic Virotherapy
7%
Chemotherapy
7%
Leukemia
7%
Ovarian Cancer
7%
Multiple Myeloma
7%
Injection
7%
Trunk
7%
Oncolytic Virus
7%
Measles Antibody
7%
Isoprenaline
7%